Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 12/2006

01.12.2006 | Original article

Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio

verfasst von: Livia Tossici-Bolt, Sandra M. A. Hoffmann, Paul M. Kemp, Rajnikant L. Mehta, John S. Fleming

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A technique is described for accurate quantification of the specific binding ratio (SBR) in [123I]FP-CIT SPECT brain images.

Methods

Using a region of interest (ROI) approach, the SBR is derived from a measure of total striatal counts that takes into account the partial volume effect. Operator intervention is limited to the placement of the striatal ROIs, a task facilitated by the use of geometrical template regions. The definition of the image for the analysis is automated and includes transaxial slices within a “slab” approximately 44 mm thick centred on the highest striatal signal. The reference region is automatically defined from the non-specific uptake in the whole brain enclosed in the slab, with exclusion of the striatal region. A retrospective study consisting of 25 normal and 30 abnormal scans—classified by the clinical diagnosis reached with the scan support—was carried out to assess intra- and inter-operator variability of the technique and its clinical usefulness. Three operators repeated the quantification twice and the variability was measured by the coefficient of variation (COV).

Results

The COVs for intra- and inter-operator variability were 3% and 4% respectively. A cutoff ∼4.5 was identified that separated normal and abnormal groups with a sensitivity, specificity and diagnostic concordance of 97%, 92% and 95% respectively.

Conclusion

The proposed technique provides a reproducible and sensitive index. It is hoped that its independence from the partial volume effect will improve consistency in quantitative measurements between centres with different imaging devices and analysis software.
Literatur
1.
Zurück zum Zitat Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I-β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9–24PubMed Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I-β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9–24PubMed
2.
Zurück zum Zitat Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Bruck T. [123I]beta-CIT and SPECT in essential tremor and Parkinson’s disease. J Neural Transm 1998;105:1213–1228PubMedCrossRef Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Bruck T. [123I]beta-CIT and SPECT in essential tremor and Parkinson’s disease. J Neural Transm 1998;105:1213–1228PubMedCrossRef
3.
Zurück zum Zitat Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503–510PubMedCrossRef Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503–510PubMedCrossRef
4.
Zurück zum Zitat Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson’s disease. Eur J Nucl Med 2001;28:1523–1528PubMedCrossRef Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson’s disease. Eur J Nucl Med 2001;28:1523–1528PubMedCrossRef
5.
Zurück zum Zitat Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. CLE differentiation of dementia with lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:130–140 Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. CLE differentiation of dementia with lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:130–140
6.
Zurück zum Zitat O’Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualised with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919–925PubMedCrossRef O’Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualised with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919–925PubMedCrossRef
7.
Zurück zum Zitat Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, et al. [123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996;46:231–237PubMed Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, et al. [123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996;46:231–237PubMed
8.
Zurück zum Zitat Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AGM, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62:133–140PubMed Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AGM, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62:133–140PubMed
9.
Zurück zum Zitat Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of [123I]FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson’s disease. Eur J Nucl Med 1997;24:68–71PubMedCrossRef Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of [123I]FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson’s disease. Eur J Nucl Med 1997;24:68–71PubMedCrossRef
10.
Zurück zum Zitat Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RB, Charney DS, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporter in healthy subjects and Parkinson’s patients. J Nucl Med 1998;39:1500–1508PubMed Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RB, Charney DS, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporter in healthy subjects and Parkinson’s patients. J Nucl Med 1998;39:1500–1508PubMed
11.
Zurück zum Zitat Mozley PD, Scheneider JS, Acton PD, Plössl K, Stern MB, Siderowf A, et al. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson’s disease and in healthy volunteers. J Nucl Med 2000;41:584–589PubMed Mozley PD, Scheneider JS, Acton PD, Plössl K, Stern MB, Siderowf A, et al. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson’s disease and in healthy volunteers. J Nucl Med 2000;41:584–589PubMed
12.
Zurück zum Zitat Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, et al. Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997;24:415–421PubMed Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, et al. Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997;24:415–421PubMed
13.
Zurück zum Zitat Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. Graphical, kinetic and equilibrium analyses of in vivo [123I]β-CIT binding to dopamine transporter in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982–994PubMed Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. Graphical, kinetic and equilibrium analyses of in vivo [123I]β-CIT binding to dopamine transporter in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982–994PubMed
14.
Zurück zum Zitat Booij J, Hemelaar JTGM, Speelman JD, de Bruin K, Janssen GM, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med 1999;40:753–761PubMed Booij J, Hemelaar JTGM, Speelman JD, de Bruin K, Janssen GM, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med 1999;40:753–761PubMed
15.
Zurück zum Zitat Acton PD, Meyer PT, Mozley PD, Plössl K, Kung HF. Simplified quantification of dopamine transporters in humans using [99mTc]TRODAT-1 and single-photon emission tomography. Eur J Nucl Med 2000;27:1714–1718PubMedCrossRef Acton PD, Meyer PT, Mozley PD, Plössl K, Kung HF. Simplified quantification of dopamine transporters in humans using [99mTc]TRODAT-1 and single-photon emission tomography. Eur J Nucl Med 2000;27:1714–1718PubMedCrossRef
16.
Zurück zum Zitat Costa DC, Walker Z, Dizdarevic S, Ioannides C, Gacinovic S, Walker RW, et al. Striatal binding index of FP-CIT: a simple method to separate Parkinson’s disease patients and controls [abstract]. Eur J Nucl Med 1998;25:1069 Costa DC, Walker Z, Dizdarevic S, Ioannides C, Gacinovic S, Walker RW, et al. Striatal binding index of FP-CIT: a simple method to separate Parkinson’s disease patients and controls [abstract]. Eur J Nucl Med 1998;25:1069
17.
Zurück zum Zitat Bolt L, Fleming JS, Hoffmann SMA, Kemp PM, Costa DC. Quantifying DaTSCAN images: how automation reduces operator variability. Nucl Med Commun 2003;24:445CrossRef Bolt L, Fleming JS, Hoffmann SMA, Kemp PM, Costa DC. Quantifying DaTSCAN images: how automation reduces operator variability. Nucl Med Commun 2003;24:445CrossRef
18.
Zurück zum Zitat Fleming JS, Bolt L, Stratford JS, Kemp PM. The specific uptake size index for quantifying radiopharmaceutical uptake. Phys Med Biol 2004;49:N227–N234PubMedCrossRef Fleming JS, Bolt L, Stratford JS, Kemp PM. The specific uptake size index for quantifying radiopharmaceutical uptake. Phys Med Biol 2004;49:N227–N234PubMedCrossRef
19.
Zurück zum Zitat Blinkov SM, Glezer II. The human brain in figures and tables. A quantitative handbook. New York: Basic Books, Plenum Press; 1968. pp 166–171 Blinkov SM, Glezer II. The human brain in figures and tables. A quantitative handbook. New York: Basic Books, Plenum Press; 1968. pp 166–171
20.
Zurück zum Zitat Aylward EH, Li Q, Habbak R, Warren A, Pulsifer MB, Barta PE, et al. Basal ganglia volume in adults with Down syndrome. Psychiatry Res Neuroimaging Section 1997;74:73–82CrossRef Aylward EH, Li Q, Habbak R, Warren A, Pulsifer MB, Barta PE, et al. Basal ganglia volume in adults with Down syndrome. Psychiatry Res Neuroimaging Section 1997;74:73–82CrossRef
21.
Zurück zum Zitat JL Fleiss. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 1981MATH JL Fleiss. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 1981MATH
22.
Zurück zum Zitat Bland JM, Altman DG. Statistical method for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–310PubMed Bland JM, Altman DG. Statistical method for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–310PubMed
23.
Zurück zum Zitat Fleming JS, Alaamer AS. Influence of collimator characteristics on quantification in SPECT. J Nucl Med 1996;37:1832–1836PubMed Fleming JS, Alaamer AS. Influence of collimator characteristics on quantification in SPECT. J Nucl Med 1996;37:1832–1836PubMed
24.
Zurück zum Zitat Hashimoto J, Sasaki T, Ogawa K, Kubo A, Motomura N, Ichihara T, et al. Effects of scatter and attenuation correction on quantitative analysis of β-CIT brain SPECT. Nucl Med Commun 1999;20:159–165PubMedCrossRef Hashimoto J, Sasaki T, Ogawa K, Kubo A, Motomura N, Ichihara T, et al. Effects of scatter and attenuation correction on quantitative analysis of β-CIT brain SPECT. Nucl Med Commun 1999;20:159–165PubMedCrossRef
25.
Zurück zum Zitat Kim KM, Varrone A, Watabe H, Shidahara M, Fujita M, Innis RB, et al. Contribution of scatter and attenuation compensation to SPECT images of nonuniformly distributed brain activities. J Nucl Med 2003;44:512–519PubMed Kim KM, Varrone A, Watabe H, Shidahara M, Fujita M, Innis RB, et al. Contribution of scatter and attenuation compensation to SPECT images of nonuniformly distributed brain activities. J Nucl Med 2003;44:512–519PubMed
26.
Zurück zum Zitat Parkinson Study Group. Dopamine transporter brain imaging to assess the effect of pramipexole vs levadopa on Parkinson disease progression. JAMA 2002;13:1653–1661CrossRef Parkinson Study Group. Dopamine transporter brain imaging to assess the effect of pramipexole vs levadopa on Parkinson disease progression. JAMA 2002;13:1653–1661CrossRef
27.
Zurück zum Zitat Kuikka JT, Bergstrom KA, Ahonen A, Hiltunen J, Haukka J, Länsimies E, et al. Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging the dopamine transporter in the living human brain. Eur J Nucl Med 1995;22:356–360PubMedCrossRef Kuikka JT, Bergstrom KA, Ahonen A, Hiltunen J, Haukka J, Länsimies E, et al. Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging the dopamine transporter in the living human brain. Eur J Nucl Med 1995;22:356–360PubMedCrossRef
28.
Zurück zum Zitat Booij J, Habraken JBA, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporter with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med 1998;39:1879–1884PubMed Booij J, Habraken JBA, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporter with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med 1998;39:1879–1884PubMed
29.
Zurück zum Zitat Ichise M, Ballinger JR, Tanaka F, Moscovitch M, St. George-Hyslop PH, Raphael D, et al. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med 1998;39:1511–1518PubMed Ichise M, Ballinger JR, Tanaka F, Moscovitch M, St. George-Hyslop PH, Raphael D, et al. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med 1998;39:1511–1518PubMed
30.
Zurück zum Zitat Linke R, Gostomzyk J, Hahn K, Tatsch K. [123I]IPT binding to presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med 2000;27:1809–1812PubMedCrossRef Linke R, Gostomzyk J, Hahn K, Tatsch K. [123I]IPT binding to presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med 2000;27:1809–1812PubMedCrossRef
31.
Zurück zum Zitat Cot A, Falcón C, Crespo C, Sempau J, Pareto D, Bullich S, et al. Absolute quantification of dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction. J Nucl Med 2005;46:1497–1504PubMed Cot A, Falcón C, Crespo C, Sempau J, Pareto D, Bullich S, et al. Absolute quantification of dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction. J Nucl Med 2005;46:1497–1504PubMed
32.
Zurück zum Zitat Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, et al. [123I]-β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158–1167PubMedCrossRef Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, et al. [123I]-β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158–1167PubMedCrossRef
33.
Zurück zum Zitat Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al. Imaging serotonin and dopamine transporters with123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000;41:36–44PubMed Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al. Imaging serotonin and dopamine transporters with123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000;41:36–44PubMed
34.
Zurück zum Zitat van Dyck CH, Seibyl JP, Malison RT, Laurelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175–1181PubMed van Dyck CH, Seibyl JP, Malison RT, Laurelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175–1181PubMed
35.
Zurück zum Zitat Schwarz J, Storch A, Koch W, Pogarelli O, Radau PE, Tatsch K. Loss of dopamine transporter binding follows a single exponential rather than linear decline. J Nucl Med 2004;45:1694–1697PubMed Schwarz J, Storch A, Koch W, Pogarelli O, Radau PE, Tatsch K. Loss of dopamine transporter binding follows a single exponential rather than linear decline. J Nucl Med 2004;45:1694–1697PubMed
36.
Zurück zum Zitat Tsuchida T, Ballinger JR, Vines D, Kim YJ, Utsunomiya K, Lang AE, et al. Reproducibility of dopamine transporter density measured with 123I-FPCIT SPECT in normal control and Parkinson’s disease patients. Ann Nucl Med 2004;18:609–616PubMedCrossRef Tsuchida T, Ballinger JR, Vines D, Kim YJ, Utsunomiya K, Lang AE, et al. Reproducibility of dopamine transporter density measured with 123I-FPCIT SPECT in normal control and Parkinson’s disease patients. Ann Nucl Med 2004;18:609–616PubMedCrossRef
37.
Zurück zum Zitat Seibyl JP, Laurelle M, van Dick CH, Wallace E, Baldwin RM, Zoghbi S, et al. Reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 1996;37:222–228PubMed Seibyl JP, Laurelle M, van Dick CH, Wallace E, Baldwin RM, Zoghbi S, et al. Reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 1996;37:222–228PubMed
38.
Zurück zum Zitat Meyer PT, Sattler B, Lincke T, Seese A, Sabri O. Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems. J Nucl Med 2003;45:839–845 Meyer PT, Sattler B, Lincke T, Seese A, Sabri O. Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems. J Nucl Med 2003;45:839–845
Metadaten
Titel
Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio
verfasst von
Livia Tossici-Bolt
Sandra M. A. Hoffmann
Paul M. Kemp
Rajnikant L. Mehta
John S. Fleming
Publikationsdatum
01.12.2006
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0155-x

Weitere Artikel der Ausgabe 12/2006

European Journal of Nuclear Medicine and Molecular Imaging 12/2006 Zur Ausgabe